1242166-68-2

Usage

Uses

Used in Pharmaceutical Industry:
(3S,4R)-4-phenylpyrrolidin-3-ol hydrochloride is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique stereochemistry allows for the development of drugs with specific therapeutic applications, targeting a wide range of medical conditions.
Used in Drug Solubility and Bioavailability Enhancement:
As a hydrochloride salt, (3S,4R)-4-phenylpyrrolidin-3-ol hydrochloride is used to improve the solubility and bioavailability of the parent compound. This enhancement is essential for the compound's effectiveness in pharmaceutical formulations, ensuring that it can be efficiently absorbed and utilized by the body.
Used in Drug Development and Research:
The precise synthesis and characterization of (3S,4R)-4-phenylpyrrolidin-3-ol hydrochloride are vital for its safety and effectiveness in pharmaceutical formulations. Researchers and pharmaceutical companies use (3S,4R)-4-phenylpyrrolidin-3-ol hydrochloride in drug development and research to create new drugs with targeted therapeutic properties and improved pharmacological profiles.

Upstream product

• 849674-11-9 C₁₅H₂₁NO₃ 
• 100-58-3 phenylmagnesium bromide 

Relevant academic research and scientific papers

PYRROL-1 -YL BENZOIC ACID DERIVATES USEFUL AS MYC INHIBITORS

The present invention provides compounds of Formula (I-A), (I-B), and (I-C), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting Myc (e.g., c-Myc) activity. The p

3-HYDROXYPYRROLIDINE INHIBITORS OF 5?-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE

The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (I) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds

Design and synthesis of potent "sulfur-free" transition state analogue inhibitors of 5′-methylthioadenosine nucleosidase and 5′-methylthioadenosine phosphorylase

5′-Methylthioadenosine/S-adenosylhomocysteine nucleosidase (MTAN) is a dual substrate bacterial enzyme involved in S-adenosylmethionine (SAM) related quorum sensing pathways that regulates virulence in many bacterial species. MTANs from many bacteria are directly involved in the quorum sensing mechanism by regulating the synthesis of autoinducer molecules that are used by bacterial communities to communicate. In humans, 5′-methylthioadenosine phosphorylase (MTAP) is involved in polyamine biosynthesis as well as in purine and SAM salvage pathways and thus has been identified as an anticancer target. Previously we have described the synthesis and biological activity of several aza-C-nucleoside mimics with a sulfur atom at the 5′ position that are potent E. coli MTAN and human MTAP inhibitors. Because of the possibility that the sulfur may affect bioavailability, we were interested in synthesizing "sulfur-free" analogues. Herein we describe the preparation of a series of "sulfur-free" transition state analogue inhibitors of E. coli MTAN and human MTAP that have low nano-to picomolar dissociation constants and are potentially novel bacterial anti-infective and anticancer drug candidates.

PYRROLOTRIAZINE KINASE INHIBITORS

The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of such as TrkA, TrkB, TrkC, Jak2, Jak3 and CK2, thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.